AKT1 and breast carcinoma: In women with breast cancer, overexpression of phosphorylated AKT was associated with worse overall survival and disease-free survival, respectively, 1.52 (95% CI: 1.29–1.78) and 1.28 (95% CI: 1.13–1.45) (193).